Table 1.
Monoclonal antibodies FDA-approved or under investigation for the treatment of patients with ovarian cancer (from 2015 to August 2023).
| Generic name | Trade name/investigational name | Target | Format | Notes |
|---|---|---|---|---|
| Bevacizumab | Avastin® | VEGF | Whole antibody | FDA-approved in 2018 for ovarian cancer |
| Mirvetuximab soravtansine | Elahere® | FR-α | Whole antibody conjugated to a drug | FDA-approved in 2022 for ovarian cancer |
| Catumaxomab | Removab® | EpCAM/CD3 | Trifunctional antibody | NCT00822809 |
| Cetuximab | Erbitux® | EGF receptor | Whole antibody | NCT00086892 |
| Panitumumab | Vectibix® | EGFR | Whole antibody | NCT01388621 |
| Farletuzumab | MORAb-003 | FR-α | Whole antibody | NCT00849667 |
| Oregovomab | OvaRex® MAb-B43.13 | CA125 | Whole antibody | NCT04498117 |
| Amatuximab | MORAb-009 | Mesothelin | Whole antibody | NCT00325494 |
| Atezolizumab | Tecentriq® | PD-L1 | Whole antibody | NCT03038100 |
| Tisotumab vedotin | Tivdak® | Tissue factor (TF) | Whole antibody conjugated to a drug | NCT03657043 |
| Durvalumab | Imfinzi® | PD-L1 | Whole antibody | NCT04742075, NCT03899610 |
| Nivolumab | Opdivo® | PD-1 | Whole antibody | NCT05601752 |
| Pembrolizumab | Keytruda® | PD-1 | Whole antibody | NCT02674061, NCT02865811 |
| Ipilimumab | Yervoy® | CTLA-4 | Whole antibody | NCT02498600 |
| Sabatolimab | MBG453 | Mucin domain-3 (TIM-3) | Whole antibody | NCT02608268 |
| Spartalizumab | PDR001 | PD-1 | Whole antibody | NCT02608268 |
| Avelumab | Bavencio® | PD-L1 | Whole antibody | NCT02580058 |
| Magrolimab | Hu5F9-G4 | CD47 | Whole antibody | NCT03558139, NCT02216409 |
| - | hu3S193 | Lewis-Y | – | NCT01137071, NCT00617773 |
| Anetumab ravtansine | BAY 94–9343 | Mesothelin | Whole antibody conjugated to a drug | NCT02751918 |
| Navicixizumab | – | Vascular endothelial growth factor (VEGF) and delta-like ligand 4 (DDL4) | Bispecific | NCT03030287 |
| Lifastuzumab Vedotin | LIFA | NaPi2b | Whole antibody conjugated to a drug | NCT01911598 |
| - | TQB2450 | PD-L1 | Whole antibody | NCT04236362 |
| - | INCAGN01949 | OX40 | Whole antibody | NCT02923349 |
| - | DMUC5754A | MUC16 | Whole antibody conjugated to a drug | NCT01335958 |
| Abagovomab | – | CA125 | Whole antibody | NCT00418574 |
| Tocilizumab | Actemra® | IL-6 receptor | Whole antibody | NCT01637532 |
| Trastuzumab | Herceptin® | HER2/neu | Whole antibody | NCT00189579 |
| Ganitumab | AMG 479 | Type 1 insulin-like growth factor receptor (IGF-1R) | Whole antibody | NCT00719212 |
| Tremelimumab | Imjudo® | CTLA-4 | Whole antibody | NCT03899610 |
| Olaratumab | Lartruvo® | Platelet-derived growth factor receptor-α (PDGFR-α) | Whole antibody | NCT00913835 |
| - | DMUC4064A | MUC16 | Whole antibody conjugated to a drug | NCT02146313 |
| Pertuzumab | Perjeta® | HER2 | Whole antibody | NCT01684878 |
| Camrelizumab | SHR-1210 | PD1 | Whole antibody | NCT03827837 |
| - | RO5323441 | Placental growth factor (PlGF) | Whole antibody | NCT01148758 |
| Dostarlimab | Jemperli® | PDCD1 | Whole antibody | NCT04679064 |
| - | HuMax-IL8 | IL-8 | Whole antibody | NCT02536469 |
| - | MOv18 | FR-α | Whole antibody | NCT02546921 |
| Gatipotuzumab | PankoMab-GEX | TA-MUC1 | Whole antibody | NCT01899599, NCT01222624 |
| - | LY3022855 | CSF-1R | Whole antibody | NCT02718911 |
| Enoticumab | REGN421 | DDL4 | Whole antibody | NCT00871559 |
| Seribantumab | MM-121 | ErbB3 | Whole antibody | NCT01447706 |
| - | DKN-01 | DKK1 | Whole antibody | NCT03395080 |
| Monalizumab | IPH2201 | CD94/NKG2 | Whole antibody | NCT02671435 |
| Conatumumab | AMG-655 | TRAIL-R2 (CD262) | Whole antibody | NCT00819169 |
| - | PF-06647263 | EFNA4 | Whole antibody conjugated to a drug | NCT02078752 |
| IMGN901 | CD56 | Whole antibody | NCT00346385 | |
| Telisotuzumab | ABT-700 | c-Met | Whole antibody | NCT01472016 |
| Figitumumab | CP-751871 | IGF-1 receptor | Whole antibody | – |
| Imalumab | BAX69 | Macrophage inhibitory factor (MIF) | Whole antibody | NCT01765790 |